A Study of Apatinib in Non-triple-negative Metastatic Breast Cancer

Sponsor
Fudan University
Study ID
NCT01653561
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    The starting dose of apatinib will be 500mg/d. Two dose reductions will be allowed to 375 and then 250 mg/d.

Study Details

The hypothesis of this clinical research study is to discover if the study drug apatinib can shrink or slow the growth of pretreated non-triple-negative metastatic breast cancer.

Key Dates

Start date
Nov 30, 2011
Status verified
Aug 2013
Primary completion
Oct 31, 2012
Completion
Oct 31, 2012

Study Design

Enrollment
20 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib
    Apatinib 500mg/d

Primary Outcome Measure

PFS(Progression free survival) [ Time Frame: 8 Weeks ]

Related Studies